Venbio Global Strategic Fund Ii L.p. - Net Worth and Insider Trading
Venbio Global Strategic Fund Ii L.p. Net Worth
The estimated net worth of Venbio Global Strategic Fund Ii L.p. is at least $243 Million dollars as of 2024-11-29. Venbio Global Strategic Fund Ii L.p. is the 10% Owner of Apellis Pharmaceuticals Inc and owns about 3,579,305 shares of Apellis Pharmaceuticals Inc (APLS) stock worth over $122 Million. Venbio Global Strategic Fund Ii L.p. is the 10% Owner of Akero Therapeutics Inc and owns about 3,033,552 shares of Akero Therapeutics Inc (AKRO) stock worth over $98 Million. Venbio Global Strategic Fund Ii L.p. is also the 10% Owner of Checkmate Pharmaceuticals Inc and owns about 2,155,930 shares of Checkmate Pharmaceuticals Inc (CMPI) stock worth over $23 Million. Besides these, Venbio Global Strategic Fund Ii L.p. also holds VYNE Therapeutics Inc (VYNE) , IPI Legacy Liquidation Co (IMPLQ) , Cold Metal Products Inc (CMPI) . Details can be seen in Venbio Global Strategic Fund Ii L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Venbio Global Strategic Fund Ii L.p. has not made any transactions after 2022-05-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Venbio Global Strategic Fund Ii L.p.
Venbio Global Strategic Fund Ii L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Venbio Global Strategic Fund Ii L.p. owns 6 companies in total, including Checkmate Pharmaceuticals Inc (CMPI) , ALX Oncology Holdings Inc (ALXO) , and Akero Therapeutics Inc (AKRO) among others .
Insider Ownership Summary of Venbio Global Strategic Fund Ii L.p.
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
CMPI | Checkmate Pharmaceuticals Inc | 2022-05-16 | 10 percent owner |
ALXO | ALX Oncology Holdings Inc | 2020-07-16 | 10 percent owner & other: See Remarks |
AKRO | Akero Therapeutics Inc | 2020-07-06 | 10 percent owner |
2018-01-25 | 10 percent owner | ||
2017-11-13 | 10 percent owner | ||
2021-04-27 | 10 percent owner |
Venbio Global Strategic Fund Ii L.p. Latest Holdings Summary
Venbio Global Strategic Fund Ii L.p. currently owns a total of 6 stocks. Among these stocks, Venbio Global Strategic Fund Ii L.p. owns 3,579,305 shares of Apellis Pharmaceuticals Inc (APLS) as of November 13, 2017, with a value of $122 Million and a weighting of 50.39%. Venbio Global Strategic Fund Ii L.p. owns 3,033,552 shares of Akero Therapeutics Inc (AKRO) as of July 6, 2020, with a value of $98 Million and a weighting of 40.24%. Venbio Global Strategic Fund Ii L.p. also owns 2,155,930 shares of Checkmate Pharmaceuticals Inc (CMPI) as of May 16, 2022, with a value of $23 Million and a weighting of 9.33%. The other 3 stocks VYNE Therapeutics Inc (VYNE) , IPI Legacy Liquidation Co (IMPLQ) , Cold Metal Products Inc (CMPI) have a combined weighting of 0.04% among all his current holdings.
Latest Holdings of Venbio Global Strategic Fund Ii L.p.
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
APLS | Apellis Pharmaceuticals Inc | 2017-11-13 | 3,579,305 | 34.14 | 122,197,473 |
AKRO | Akero Therapeutics Inc | 2020-07-06 | 3,033,552 | 32.17 | 97,589,368 |
CMPI | Checkmate Pharmaceuticals Inc | 2022-05-16 | 2,155,930 | 10.50 | 22,637,265 |
VYNE | VYNE Therapeutics Inc | 2018-01-25 | 20,299 | 2.95 | 59,882 |
IMPLQ | IPI Legacy Liquidation Co | 2021-04-27 | 2,759,791 | 0.02 | 41,397 |
CMPI | Cold Metal Products Inc | 2020-08-11 | 3,673,374 | 0.00 | 0 |
Holding Weightings of Venbio Global Strategic Fund Ii L.p.
Venbio Global Strategic Fund Ii L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Venbio Global Strategic Fund Ii L.p. has made a total of 0 transactions in Apellis Pharmaceuticals Inc (APLS) over the past 5 years. The most-recent trade in Apellis Pharmaceuticals Inc is the acquisition of 127,515 shares on November 13, 2017, which cost Venbio Global Strategic Fund Ii L.p. around $2 Million.
According to the SEC Form 4 filings, Venbio Global Strategic Fund Ii L.p. has made a total of 12 transactions in Akero Therapeutics Inc (AKRO) over the past 5 years, including 0 buys and 12 sells. The most-recent trade in Akero Therapeutics Inc is the sale of 116,467 shares on July 6, 2020, which brought Venbio Global Strategic Fund Ii L.p. around $4 Million.
According to the SEC Form 4 filings, Venbio Global Strategic Fund Ii L.p. has made a total of 7 transactions in Checkmate Pharmaceuticals Inc (CMPI) over the past 5 years, including 0 buys and 7 sells. The most-recent trade in Checkmate Pharmaceuticals Inc is the sale of 131,650 shares on May 16, 2022, which brought Venbio Global Strategic Fund Ii L.p. around $1 Million.
More details on Venbio Global Strategic Fund Ii L.p.'s insider transactions can be found in the Insider Trading History of Venbio Global Strategic Fund Ii L.p. table.Insider Trading History of Venbio Global Strategic Fund Ii L.p.
- 1
Venbio Global Strategic Fund Ii L.p. Trading Performance
GuruFocus tracks the stock performance after each of Venbio Global Strategic Fund Ii L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Venbio Global Strategic Fund Ii L.p. is -19.94%. GuruFocus also compares Venbio Global Strategic Fund Ii L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Venbio Global Strategic Fund Ii L.p. within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Venbio Global Strategic Fund Ii L.p.'s insider trading performs compared to the benchmark.
Performance of Venbio Global Strategic Fund Ii L.p.
Venbio Global Strategic Fund Ii L.p. Ownership Network
Venbio Global Strategic Fund Ii L.p. Owned Company Details
What does Checkmate Pharmaceuticals Inc do?
Who are the key executives at Checkmate Pharmaceuticals Inc?
Venbio Global Strategic Fund Ii L.p. is the 10 percent owner of Checkmate Pharmaceuticals Inc. Other key executives at Checkmate Pharmaceuticals Inc include director & Chief Executive Officer Alan Bash , 10 percent owner Novo Holdings A/s , and director & Chief Scientific Officer Arthur M Krieg .
Checkmate Pharmaceuticals Inc (CMPI) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Checkmate Pharmaceuticals Inc (CMPI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Checkmate Pharmaceuticals Inc (CMPI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Checkmate Pharmaceuticals Inc (CMPI)'s detailed insider trading history can be found in Insider Trading Tracker table.
Checkmate Pharmaceuticals Inc Insider Transactions
Venbio Global Strategic Fund Ii L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Venbio Global Strategic Fund Ii L.p.. You might contact Venbio Global Strategic Fund Ii L.p. via mailing address: 1700 Owens Street, Suite 595, San Francisco Ca 94158.